Tartrate salt of a substituted dipeptide
CA 2294422 C · Owner: Pfizer Products Inc. · Inventors: Dasilva-Jardine, Paul Andrew; Lefker, Bruce Allen; Carpino, Philip Albert
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
This invention is directed to the (L)-tartaric acid salt of 2-amino-N-{1- (2,4difluoro-benzyloxymethyl) -2-oxo-2-3-oxo-3a-pyridin-2-ylmethyl-2- (2,2,2trifluoroethyl)-2,3,3a, 4,6,7-hexahydro-pyrazolo4,3-c pyridin-5-yl-ethyl} - 2-methyl-propionamide which is a growth hormone secretagogue and as such is useful for increasing the level of endogenous growth hormone. In another aspect, this invention provides certain intermediates which are useful in the synthesis of the foregoing compound. The (L)-tartaric acid salt of the compound of this invention is useful for the treatment and/or prevention of osteoporosis, insulin resistance and other conditions or diseases associated with growth …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed June 5, 1998 and granted July 22, 2003. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended June 5, 2018.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by June 5, 2020.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.